223 related articles for article (PubMed ID: 10397375)
1. Comparison of the in vitro activity of and pathogen responses to sparfloxacin with those of other agents in the treatment of respiratory tract, urinary tract, and skin and skin-structure infections.
Dowzicky M; Nadler H; Dorr MB; Acusta A; Talbot GH
Clin Ther; 1999 May; 21(5):790-805; discussion 789. PubMed ID: 10397375
[TBL] [Abstract][Full Text] [Related]
2. Levofloxacin and sparfloxacin: new quinolone antibiotics.
Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
Ballow CH; Jones RN; Johnson DM; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
[TBL] [Abstract][Full Text] [Related]
4. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
Martin SJ; Jung R; Garvin CG
Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
[TBL] [Abstract][Full Text] [Related]
5. Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group.
Henry DC; Nenad RC; Iravani A; Tice AD; Mansfield DL; Magner DJ; Dorr MB; Talbot GH
Clin Ther; 1999 Jun; 21(6):966-81. PubMed ID: 10440621
[TBL] [Abstract][Full Text] [Related]
6. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
Pfaller MA; Ehrhardt AF; Jones RN
Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
8. Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections.
Lipsky BA; Miller B; Schwartz R; Henry DC; Nolan T; McCabe A; Magner DJ; Talbot GH
Clin Ther; 1999 Apr; 21(4):675-90. PubMed ID: 10363733
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.
Richard MP; Aguado AG; Mattina R; Marre R
J Antimicrob Chemother; 1998 Feb; 41(2):207-14. PubMed ID: 9533462
[TBL] [Abstract][Full Text] [Related]
10. A review of worldwide experience with sparfloxacin in the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis.
Finch RG
Int J Antimicrob Agents; 1999 Jun; 12(1):5-17. PubMed ID: 10389642
[TBL] [Abstract][Full Text] [Related]
11. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.
Lipsky BA; Dorr MB; Magner DJ; Talbot GH
Clin Ther; 1999 Jan; 21(1):148-59. PubMed ID: 10090432
[TBL] [Abstract][Full Text] [Related]
12. A critical review of the fluoroquinolones: focus on respiratory infections.
Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
[TBL] [Abstract][Full Text] [Related]
13. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.
Bhavnani SM; Andes DR
Pharmacotherapy; 2005 May; 25(5):717-40. PubMed ID: 15899734
[TBL] [Abstract][Full Text] [Related]
14. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group.
DeAbate CA; Henry D; Bensch G; Jubran A; Chodosh S; Harper L; Tipping D; Talbot GH
Chest; 1998 Jul; 114(1):120-30. PubMed ID: 9674458
[TBL] [Abstract][Full Text] [Related]
15. Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.
Goa KL; Bryson HM; Markham A
Drugs; 1997 Apr; 53(4):700-25. PubMed ID: 9098667
[TBL] [Abstract][Full Text] [Related]
16. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
Nightingale CH
Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
[TBL] [Abstract][Full Text] [Related]
17. Sparfloxacin: a review.
Schentag JJ
Clin Ther; 2000 Apr; 22(4):372-87; discussion 371. PubMed ID: 10823360
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
[TBL] [Abstract][Full Text] [Related]
20. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group.
Henry D; Ellison W; Sullivan J; Mansfield DL; Magner DJ; Dorr MB; Talbot GH
Antimicrob Agents Chemother; 1998 Sep; 42(9):2262-6. PubMed ID: 9736546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
